Oncolix Appoints Two Members to Its Board of Directors
October 04 2017 - 08:50AM
Board Members bring Clinical and Manufacturing
Expertise to Clinical-Stage Biopharmaceutical Company
Oncolix, Inc. (OTC PINK:AEPP) (the “Company”), a biotechnology
company focused on gynecological cancers, announced on October 4,
2017, the Board of Directors voted to increase the number of
directors to three from the current two and elected Jerry R.
Youkey, M.D., and Dale Zajicek to serve on the Company’s Board of
Directors. Mr. Zajicek is the first independent board member of the
company.
Dr. Youkey and Mr. Zajicek have served as
Directors of the Company’s wholly owned subsidiary, Oncolix, Inc.,
(a Delaware corporation) since 2007. In connection with such
action, J. Donald Payne resigned as a director of the Company but
continues to serve as its secretary. Michael T. Redman, chief
executive officer of Oncolix, continues to serve as the Company’s
third director. The term of all directors continues until their
reelection or replacement by action of the stockholders of the
Company.
“Following the completion of the merger in
August 2017, we have been focused on building an innovative
biopharmaceutical company with the objective of developing and
launching our lead candidate, Prolanta™, to treat ovarian and other
cancers,” said Michael T. Redman, president and CEO of Oncolix.
“Part of that process is to build the public company infrastructure
that will first fulfill the OTC-QB requirement to have at least two
independent directors and, ultimately, to qualify for a NASDAQ
listing. The appointment of Mr. Zajicek as an independent director
assists with that objective. In addition, both appointees have
already made valuable contributions and will be instrumental in
adding additional world-class board members. Oncolix will soon be
adding an independent fourth director, which will also fulfill the
OTC-QB requirement.”
Jerry R. Youkey, M.D.
Jerry R. Youkey, M.D., joined Greenville Health
System (GHS) in 1998, and currently serves as GHS Executive Vice
President and Chief Academic Officer, reporting to the CEO. GHS is
an eight-campus integrated delivery system with 1,756 beds,
employing approximately 14,000 employees and 1,000 medical
doctors. Since 2011, Dr. Youkey has additionally served as
Founding Dean of University of South Carolina School of Medicine
Greenville and in 2015, was appointed University of South Carolina
Associate provost for Health Sciences Greenville.
Dr. Youkey served a rotating internship and
general surgery residency at William Beaumont Army Medical Center,
El Paso, TX, and a fellowship in peripheral vascular surgery at
Walter Reed Army Medical Center, Washington D.C. He also served in
the U.S. Army and was honorably discharged in August 1984, after
attaining the rank of Colonel, Medical Corps. Dr. Youkey served as
Chief, Department of Surgery and Director, Peripheral Vascular
Surgery Fellowship Program at Geisinger Medical Center, Danville,
PA, prior to coming to Greenville. He is certified by the American
Board of Surgery in general vascular surgery.
He is widely published in his specialty field of
general vascular surgery, having authored books, abstracts and
journal articles. He holds the academic appointment of Professor
and Associate Dean at the University of South Carolina, Columbia,
SC. He received his B.A. from Stanford University, Palo Alto, CA,
his medical degree from the Medical College of Wisconsin,
Milwaukee, WI and is a member of numerous professional societies
and organizations.
Dale Zajicek
Mr. Zajicek has over 37 years of experience in
the pharmaceutical and biotechnology industry. In 2015, he retired
as President of BioVectra, Inc., a company he joined in 1995.
Following his promotion to Chief Operating Officer of BioVectra in
2005, he was responsible for growth of the firm’s contract
manufacturing and drug development efforts, with the firm filing
numerous Drug Master Files (DMF) and Investigational New Drug
applications (IND) and supported the New Drug Applications for
numerous clients. Mr. Zajicek successfully led BioVectra in the
development of generic docetaxel, and obtained “first to file”
status for this oncology drug. BioVectra partnered the product with
Sandoz for the U.S. market, and other marketing firms for markets
in Canada, Europe, Middle East, North Africa, and South America.
Under Mr. Zajicek’s leadership, BioVectra has developed
capabilities in microbial fermentation for protein-based and small
molecule drugs, as well as combining biotech processing with
synthetic capabilities to perform unique chemistries and
conjugations of large to small molecules.
Prior to joining BioVectra, Mr. Zajicek held
positions in manufacturing operations, engineering, research and
product development, and business development at G.D. Searle and
The NutraSweet Company. Mr. Zajicek holds a B.S. in Chemical
Engineering from Illinois Institute of Technology and a B.S. in
Business Administration from Elmhurst College.
Corporate contact:Michael RedmanP: 281-402-3167E:
mredman@oncolixbio.com
Investor contact:The Ruth GroupRobert FlammP: 646-536-7017E:
rflamm@theruthgroup.com